Approval Background

The EMA officially approved Nucala (Mepolizumab) as a treatment for severe eosinophilic asthma on December 1, 2015. Key evidence supporting this approval came from Phase 3 clinical trials, which demonstrated a significant reduction in the annual number of acute exacerbations and a decrease in steroid use. This therapeutic agent is a human monoclonal antibody that inhibits IL-5, thereby blocking eosinophil activity.

Competitive Landscape

Reslizumab and Benralizumab, which target the same IL-5 pathway, have already entered the European market. However, Nucala offers a differentiating advantage with an extended administration interval of 4 to 8 weeks, enhancing patient convenience. Furthermore, there is anticipation that GSK's global marketing network can create synergy with existing asthma biologics.

Insurance Coverage and Market Access Limitations

European health authorities require cost-effectiveness analyses, and reimbursement is expanded only when the efficacy in reducing acute exacerbations is sufficiently demonstrated. In some countries, limited reimbursement may occur if the price is not competitive compared to existing treatments. Therefore, local pricing strategies and patient support programs will play a crucial role in market penetration.

Market Size Outlook

Severe eosinophilic asthma patients account for approximately 5-10% of all asthma patients, and considering that the total number of asthma patients in Europe is about 30 million, there is a potential market of several million. Due to the high value-added nature of biologics, the potential for revenue growth is considered high.